Trastuzumab cardio-oncology: lessons learned

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Trastuzumab is a key therapy for HER2-positive breast cancer.
• A subset of patients experience cardiac dysfunction with trastuzumab treatment.
• HER2 signaling in cardiomyocytes may be crucial for cardioprotection.

Purpose of the Study:

• To review the cardiac risks associated with trastuzumab.
• To outline strategies for mitigating trastuzumab-induced cardiotoxicity.
• To discuss management of cardiac dysfunction during trastuzumab therapy.

Main Methods:

• Review of existing literature on trastuzumab and cardiac function.
• Analysis of risk factors for trastuzumab-associated cardiotoxicity.
• Discussion of monitoring and intervention strategies.

Main Results:

• Trastuzumab significantly improves outcomes in HER2-positive breast cancer.
• Cardiac dysfunction is a known, albeit uncommon, side effect.
• Pre-treatment risk factor assessment and ongoing cardiac monitoring are vital.
• Early intervention can allow for trastuzumab re-initiation.

Conclusions:

• Proactive cardiac risk assessment and monitoring are essential for patients receiving trastuzumab.
• Management strategies can minimize cardiac risks and optimize treatment.
• Nonanthracycline regimens may benefit cardiac-compromised patients.